Misek David E, Imafuku Yugi, Hanash Samir M
Department of Pediatrics, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, Michigan, 48109-0656, USA.
Pharmacogenomics. 2004 Dec;5(8):1129-37. doi: 10.1517/14622416.5.8.1129.
The sequencing of the human genome has had an enormous impact on the proteomic analysis of cancer by providing a sequence-based framework for understanding the human proteome of tumor cells, tissues, and biological fluids. There is intense interest in applying proteomic technologies to uncover, at the protein level, processes involved in neoplastic transformation and new biomarkers that correlate with early diagnosis, as well as to accelerate the development of new therapeutic targets. To that effect, new technologies are being developed in order to meet the needs for the high throughput and high sensitivity that is required for cancer-related applications of proteomics. These innovative technologies have greatly enhanced our ability to separate and characterize complex protein mixtures, and have aided our ability to identify proteins with greater sensitivity, thereby providing the groundwork for future scientific breakthroughs and possibly providing impetus for the development of personalized cancer therapy.
人类基因组测序通过提供一个基于序列的框架来理解肿瘤细胞、组织和生物流体中的人类蛋白质组,对癌症的蛋白质组分析产生了巨大影响。人们对应用蛋白质组技术在蛋白质水平上揭示肿瘤转化过程和与早期诊断相关的新生物标志物,以及加速新治疗靶点的开发有着浓厚兴趣。为此,正在开发新技术以满足蛋白质组学在癌症相关应用中所需的高通量和高灵敏度的要求。这些创新技术极大地提高了我们分离和表征复杂蛋白质混合物的能力,并有助于我们以更高的灵敏度鉴定蛋白质,从而为未来的科学突破奠定基础,并可能为个性化癌症治疗的发展提供动力。